5-aminolaevulinic acid photodynamic therapy in a transgenic mouse model of skin melanoma.
Photodynamic therapy (PDT) is widely used to treat preneoplastic skin lesions and non-melanoma skin tumours. Studies analyzing the effects of PDT on malignant melanoma have yielded conflicting results. On the one hand, melanoma cell lines in culture as well as cell lines transplanted into experimental animals were sensitive to PDT. On the other hand, spontaneous melanomas of human patients responded poorly to most PDT regimens tested so far. Here, we analyzed effects of 5-aminolaevulinic acid (5-ALA)-based PDT on melanoma cell lines and on experimental melanomas. To mimic the clinical situation as closely as possible, metallothionein-I/ret (MT-ret) mice, a transgenic model of skin melanoma development, were used. Optimal doses of 5-ALA as well as energy doses and power densities were determined in vitro using a cell line (Mel25) established by us from a melanoma of an MT-ret transgenic mouse as well as commercially available human and mouse melanoma cell lines. Treatment with light irradiation alone had no effect. In combination with 5-ALA, however, this illumination readily induced the death of all mouse and human melanoma cell lines examined. Still, 5-ALA PDT caused only minor focal regressive changes including haemorrhages and fibrosis of MT-ret melanomas in vivo and did not significantly delay tumour growth. These results show that, even though MT-ret melanoma cells are vulnerable to 5-ALA PDT in vitro, malignant MT-ret melanomas in vivo are quite resistant to this type of therapy at doses which are highly effective in vitro.
Córdoba
F
F
Division of Neuropathology, Institute of Pathology, University of Bern, Murtenstrasse, Bern, Switzerland.
Braathen
L R
LR
Weissenberger
J
J
Vallan
C
C
Kato
M
M
Nakashima
I
I
Weis
J
J
von Felbert
V
V
D000622:Aminolevulinic Acid / Q000627:therapeutic use*; D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival; D004195:Disease Models, Animal; D005355:Fibrosis; D005434:Flow Cytometry; D006801:Humans; D008027:Light; D008545:Melanoma / Q000235:genetics / Q000628:therapy*; D008546:Melanoma, Experimental / Q000235:genetics / Q000628:therapy*; D051379:Mice; D008822:Mice, Transgenic; D041681:NIH 3T3 Cells; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000235:genetics / Q000628:therapy*; D013778:Tetrazolium Salts / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D014343:Trypan Blue / Q000494:pharmacology
D017319:Photosensitizing Agents; D013778:Tetrazolium Salts; D013844:Thiazoles; D000622:Aminolevulinic Acid; C022616:thiazolyl blue; D014343:Trypan Blue